Eli Lilly EBITDA Margin 2012-2026 | LLY
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Eli Lilly (LLY) over the last 10 years. The current EBITDA margin for Eli Lilly as of March 31, 2026 is
Unlock Macrotrends Premium
Start 7-Day Free Trial
Eli Lilly EBITDA Margin Historical Data
Date
TTM Revenue
TTM EBITDA
EBITDA Margin
2025-12-31
$65.18B
$28.30B
43.42%
2025-09-30
$59.42B
$24.54B
41.30%
2025-06-30
$53.26B
$18.70B
35.10%
2025-03-31
$49.00B
$15.91B
32.47%
2024-12-31
$45.04B
$14.67B
32.56%
2024-09-30
$40.86B
$9.27B
22.68%
2024-06-30
$38.92B
$11.11B
28.55%
2024-03-31
$35.93B
$9.04B
25.16%
2023-12-31
$34.12B
$7.99B
23.40%
2023-09-30
$32.07B
$10.40B
32.41%
2023-06-30
$29.52B
$8.60B
29.13%
2023-03-31
$27.69B
$7.67B
27.68%
2022-12-31
$28.54B
$8.65B
30.30%
2022-09-30
$29.24B
$8.80B
30.10%
2022-06-30
$29.07B
$9.03B
31.05%
2022-03-31
$29.32B
$9.24B
31.51%
2021-12-31
$28.32B
$7.91B
27.92%
2021-09-30
$27.76B
$7.90B
28.47%
2021-06-30
$26.73B
$7.28B
27.22%
2021-03-31
$25.49B
$7.02B
27.56%
2020-12-31
$24.54B
$7.38B
30.08%
2020-09-30
$23.21B
$6.76B
29.13%
2020-06-30
$22.95B
$6.85B
29.83%
2020-03-31
$23.09B
$7.07B
30.62%
2019-12-31
$22.32B
$6.21B
27.81%
2019-09-30
$21.84B
$5.71B
26.15%
2019-06-30
$21.67B
$5.75B
26.54%
2019-03-31
$21.62B
$4.43B
20.47%
2018-12-31
$21.49B
$5.14B
23.93%
2018-09-30
$19.12B
$4.59B
24.00%
2018-06-30
$19.47B
$3.75B
19.23%
2018-03-31
$19.71B
$4.92B
24.97%
2017-12-31
$19.97B
$3.57B
17.88%
2017-09-30
$22.47B
$3.90B
17.37%
2017-06-30
$22.01B
$4.33B
19.65%
2017-03-31
$21.59B
$4.03B
18.65%
2016-12-31
$21.22B
$4.76B
22.41%
2016-09-30
$20.84B
$4.41B
21.14%
2016-06-30
$20.61B
$4.39B
21.30%
2016-03-31
$20.18B
$4.34B
21.49%
2015-12-31
$19.96B
$4.12B
20.63%
2015-09-30
$19.71B
$4.10B
20.78%
2015-06-30
$19.62B
$3.72B
18.94%
2015-03-31
$19.58B
$3.71B
18.93%
2014-12-31
$19.62B
$4.04B
20.59%
2014-09-30
$20.30B
$4.62B
22.76%
2014-06-30
$21.20B
$5.57B
26.29%
2014-03-31
$22.20B
$6.21B
27.96%
2013-12-31
$23.11B
$6.82B
29.49%
2013-09-30
$23.26B
$6.94B
29.84%
2013-06-30
$22.93B
$6.56B
28.59%
2013-03-31
$22.60B
$6.25B
27.67%
2012-12-31
$22.60B
$6.20B
27.41%
2012-09-30
$22.69B
$6.15B
27.11%
2012-06-30
$23.40B
$6.59B
28.15%
2012-03-31
$24.05B
$6.97B
28.97%
2011-12-31
$24.29B
$6.90B
28.42%
2011-09-30
$24.43B
$7.27B
29.74%
2011-06-30
$23.93B
$7.42B
30.99%
2011-03-31
$23.43B
$7.60B
32.44%
2010-12-31
$23.08B
$7.86B
34.05%
2010-09-30
$22.82B
$7.11B
31.15%
2010-06-30
$22.73B
$7.01B
30.83%
2010-03-31
$22.28B
$6.78B
30.46%
2009-12-31
$21.84B
$6.89B
31.53%
2009-09-30
$21.11B
$3.06B
14.51%
2009-06-30
$20.75B
$2.77B
13.37%
2009-03-31
$20.61B
$2.42B
11.72%
2008-12-31
$20.37B
$1.81B
8.90%
2008-09-30
$20.36B
$6.10B
29.98%
2008-06-30
$19.74B
$5.87B
29.75%
2008-03-31
$19.22B
$5.51B
28.69%
2007-12-31
$18.63B
$5.10B
27.39%
2007-09-30
$17.69B
$4.94B
27.94%
2007-06-30
$16.97B
$4.73B
27.89%
2007-03-31
$16.20B
$4.75B
29.30%
2006-12-31
$15.69B
$4.93B
31.40%
2006-09-30
$15.33B
$4.90B
31.99%
2006-06-30
$15.06B
$4.76B
31.58%
2006-03-31
$14.86B
$4.60B
30.95%
2005-12-31
$14.65B
$4.38B
29.88%
2005-09-30
$14.41B
$4.25B
29.50%
2005-06-30
$14.09B
$4.16B
29.53%
2005-03-31
$13.98B
$4.17B
29.83%
2004-12-31
$13.86B
$3.87B
27.89%
2004-09-30
$13.68B
$3.78B
27.63%
2004-06-30
$13.54B
$3.83B
28.32%
2004-03-31
$13.07B
$3.78B
28.93%
2003-12-31
$12.58B
$4.05B
32.19%
2003-09-30
$12.07B
$4.05B
33.52%
2003-06-30
$11.72B
$3.91B
33.32%
2003-03-31
$11.41B
$3.82B
33.52%
2002-12-31
$11.08B
$3.74B
33.72%
2002-09-30
$10.95B
$3.51B
32.06%
2002-06-30
$11.04B
$3.50B
31.73%
2002-03-31
$11.30B
$3.76B
33.25%
2001-12-31
$11.54B
$3.99B
34.60%
2001-09-30
$11.69B
$4.23B
36.14%
2001-06-30
$11.63B
$4.43B
38.09%
2001-03-31
$11.22B
$4.20B
37.46%
2000-12-31
$10.86B
$4.00B
36.78%
2000-09-30
$10.71B
$4.07B
37.98%
2000-06-30
$10.48B
$3.94B
37.62%
2000-03-31
$10.20B
$3.85B
37.72%
1999-12-31
$10.00B
$3.80B
38.02%
1999-09-30
$9.82B
$4.11B
41.87%
1999-06-30
$9.81B
$4.00B
40.82%
1999-03-31
$9.81B
$3.91B
39.88%
1998-12-31
$9.82B
$3.90B
39.69%
1998-09-30
$9.44B
$3.11B
32.97%
1998-06-30
$9.03B
$2.97B
32.92%
1998-03-31
$8.69B
$2.90B
33.39%
1997-12-31
$8.37B
$2.82B
33.72%
1997-09-30
$8.17B
$2.91B
35.58%
1997-06-30
$7.82B
$2.82B
36.02%
1997-03-31
$7.52B
$2.71B
36.00%
1996-12-31
$7.35B
$2.59B
35.26%
1996-09-30
$7.09B
$2.37B
33.41%
1996-06-30
$6.91B
$2.20B
31.85%
1996-03-31
$6.83B
$2.08B
30.51%
1995-12-31
$6.76B
$1.98B
29.32%
1995-09-30
$6.51B
$1.95B
29.93%
1995-06-30
$6.39B
$1.92B
30.01%
1995-03-31
$6.45B
$2.22B
34.38%
1994-12-31
$6.04B
$2.13B
35.20%
1994-09-30
$6.30B
$2.15B
34.20%
1994-06-30
$6.32B
$2.09B
33.07%
1994-03-31
$6.20B
$1.79B
28.81%
1993-12-31
$6.45B
$1.83B
28.28%
1993-09-30
$6.31B
$1.87B
29.63%
1993-06-30
$6.25B
$1.67B
26.68%
1993-03-31
$6.17B
$1.65B
26.73%
1992-12-31
$6.17B
$1.72B
27.91%
1992-09-30
$6.09B
$1.66B
27.33%
1992-06-30
$5.95B
$1.86B
31.27%
1992-03-31
$5.85B
$1.85B
31.67%
1991-12-31
$5.73B
$1.77B
30.88%
1991-09-30
$5.60B
$1.72B
30.73%
1991-06-30
$5.54B
$1.68B
30.28%
1991-03-31
$5.39B
$1.61B
29.79%
1990-12-31
$5.19B
$1.54B
29.64%
1990-09-30
$4.53B
$1.37B
30.12%
1990-06-30
$4.30B
$1.25B
29.10%
1990-03-31
$4.19B
$1.19B
28.46%
1989-12-31
$4.18B
$1.16B
27.87%
1989-09-30
$3.97B
$1.07B
26.86%
1989-06-30
$3.87B
$1.05B
27.12%
1989-03-31
$3.76B
$1.00B
26.51%
1988-12-31
$3.61B
$0.92B
25.53%
1988-09-30
$3.64B
$0.64B
17.67%
1988-06-30
$3.66B
$0.63B
17.24%
1988-03-31
$3.66B
$0.61B
16.79%
1987-12-31
$3.65B
$0.58B
16.02%
Sector
Industry
Market Cap
Revenue
Medical Large Cap Pharmaceutical $887.629B
$65.179B
Eli Lilly and Company, one of the world's largest pharmaceutical companies, boasts a diversified product profile including a solid lineup of new successful drugs. It also has a dependable pipeline as it navigates through challenges like patent expirations of several drugs and rising pricing pressure on its U.S. diabetes franchise. Its pharmaceutical product categories are neuroscience, diabetes, oncology, immunology and others. Over the past few years, Lilly has been actively seeking acquisitions and in-licensing deals to boost its product portfolio and pipeline. The purchase of ImClone Systems brought with it cancer compound, Erbitux. The acquisition of ICOS Corporation gave Lilly full control over erectile dysfunction drug, Cialis. Its other acquisitions include Hypnion, Inc., CoLucid Pharmaceuticals added Reyvow for acute migraine, Loxo Oncology and Dermira. Lilly has collaboration agreements with several companies including Incyte, Boehringer Ingelheim and Innovent Biologics among others.
